ABPI response to the Goldacre Review

The Goldacre Review has been published, with recommendations for how to build efficient and safe use of health data for research and analysis.

We are committed to working with partners to ensure that the necessary data infrastructure is built, curated and accessed as safely and effectively as possible Colette Goldrick

In response, Colette Goldrick, Executive Director, Research, Strategy and Partnerships, said:

"We share Professor Goldacre’s view that the UK's health data assets have a unique potential to drive a new era of life sciences research, and ultimately save and improve lives. The report contains practical recommendations to overcome longstanding barriers. As a sector, we are committed to working with partners to ensure that the necessary data infrastructure is built, curated and accessed as safely and effectively as possible.”

TAGS

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.